Form 4: Inhibikase Therapeutics CEO Acquires 45,000 Stock Options
SEC Form 4 Filing
Milton H. Werner, President and CEO of Inhibikase Therapeutics, Inc., reports the acquisition of 45,000 stock options on April 1, 2024.
Summary
- On April 1, 2024, Milton H. Werner, the President and CEO of Inhibikase Therapeutics, Inc., acquired 45,000 stock options.
- The exercise price of these options is $2.16.
- The options vest over time, with one-third vesting on April 1, 2025, and the remainder vesting in 24 equal monthly installments starting April 2025, contingent upon continued employment.
- The expiration date for these options is April 1, 2031.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as officers and directors, trade in their company's stock. This filing indicates compensation in the form of stock options.
Stakeholder Impact
- The granting of stock options aligns the CEO's interests with those of the shareholders, incentivizing him to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of transaction: CEO acquired 45,000 stock options. |
| 04/01/2025 | One-third of the options will vest and become exercisable. |
| 04/01/2031 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.